Pharma Drug Discovery news

  Given their ability to selectively direct a cell mediated immune response against cancer cells and, thereby, offer prolonged periods of disease remission, several CAR-T cell therapies are expected to achieve blockbuster status   Roots Analysis is pleased to announce the publication of its recent study, titled, “ CAR-T Cell Therapies Market (3rd Edition) by Target Indications (NHL, Multiple Myeloma, Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, Follicular Lymphoma, Mantle Cell Lymphoma, Hepatocellular Carcinoma and Others), Target Antigens (CD19, BCMA, CD19 / CD22, GPC3 and EGFR), Key Players and Key Geographies (North America, Europe, Asia Pacific, Latin America, Middle East and North Africa, and Rest of the World) – Industry Trends and Global Forecasts, 2021-2030 ”   The features an extensive study of the current market landscape and the future potential of CAR-T cell therapies. The report highlights the efforts of both industry players and acade...

  To order this detailed 500+ page report, please visit this - https://www.rootsanalysis.com/reports/view_document/stem-cells-market/296.html   Key Inclusions §   A detailed assessment of the current market landscape featuring over 280 stem cell-based therapies approved / under clinical development, including information on drug / therapy developer(s) (such as year of establishment, company size and location of headquarters), phase of development (marketed, phase III, phase II, phase I), source of stem cells (allogeneic and autologous), origin of stem cells (adult and embryonic), type of stem cells (hematopoietic, mesenchymal, progenitor and others), stem cell lineage (amniotic fluid, adipose tissue, bone marrow, cardiosphere, chondrocytes, corneal tissue, cord blood, dental pulp, neural tissue   placenta, peripheral blood, stromal cells   and others), stem cell potency (multipotent and pluripotent), target indication(s), key therapeutic area(s), route of...